Beloranib, an [[analog (chemistry)|analog]] of the natural chemical compound [[fumagillin]], is an [[enzyme inhibitor|inhibitor]] of the enzyme [[METAP2]].<ref>{{cite journal | pmid = 15523682 | year = 2005 | last1 = Chun | first1 = E | last2 = Han | first2 = CK | last3 = Yoon | first3 = JH | last4 = Sim | first4 = TB | last5 = Kim | first5 = YK | last6 = Lee | first6 = KY | title = Novel inhibitors targeted to methionine aminopeptidase 2 (MetAP2) strongly inhibit the growth of cancers in xenografted nude model | volume = 114 | issue = 1 | pages = 124–30 | doi = 10.1002/ijc.20687 | journal = International Journal of Cancer. Journal International Du Cancer}}</ref>  It was originally designed as [[angiogenesis inhibitor]] for the treatment of cancer.<ref>{{cite journal | pmid = 15684472 | year = 2005 | last1 = Kim | first1 = EJ | last2 = Shin | first2 = WH | title = General pharmacology of CKD-732, a new anticancer agent: effects on central nervous, cardiovascular, and respiratory system | volume = 28 | issue = 2 | pages = 217–23 | journal = Biological & Pharmaceutical Bulletin | doi=10.1248/bpb.28.217}}</ref>  However, once the potential anti-obesity effects of METAP2 inhibition became apparent, the clinical development began to focus on these effects and beloranib has shown positive results in preliminary clinical trials for this indication.<ref>{{cite web | url = http://www.drugs.com/clinical_trials/zafgen-announces-positive-topline-phase-1b-data-zgn-433-obesity-10955.html | title = Zafgen Announces Positive Topline Phase 1b Data for ZGN-433 in Obesity  | date = 5 January 2011 | work = MedNews | publisher = Drugs.com }}</ref><ref>{{cite web | url = http://www.dailymail.co.uk/health/article-1346167/Fat-busting-pill-ZGN-433-helps-obese-shed-2-pounds-week-dieting.html | title = Fat-busting pill helps obese to shed two pounds a week - without changing their diets | publisher = ''UK Daily Mail'' | date = 11 January 2011}}</ref>
